Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. - Wikidata - awgldk - TriplyDB

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

http://www.wikidata.org/entity/Q37828337

about

GLP-1 and cardioprotection: from bench to bedside Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial DPP-4 inhibitors and lipids: systematic review and meta-analysis.HD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies.Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men.Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials.In vivo efficacy of HD0471953: a novel GPR119 agonist for the treatment of type 2 diabetes mellitus.GLP-1: benefits beyond pancreas.Response: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

P2860

Q27024984-28590F24-1A72-4C71-B9FD-3616FB7FA4D0 Q28257600-662E6E64-5DF6-4FDC-99CD-06A7F51D17CF Q34116689-E4D03C3A-7489-4E50-B924-1CB34243568A Q34360545-FDB1E9C5-54B0-4EE2-AC68-446E45B2754B Q36766657-00F55790-CA76-4AF0-A9B6-213BCB57A0BB Q37023878-4F8C4AC6-8B1C-4353-A493-93F42C485E95 Q37412882-C313D754-7431-44BD-BF7D-11FBB08482B6 Q38238288-92C866CC-B74C-4BFC-8A92-AD3FCE3423DC Q42872676-44C7B437-1EA8-4225-8682-340E41CB7482 Q51301791-E68F60F4-BBFC-458F-B4D2-E5E7E6613D49 Q51367101-6A73BBDC-E6A6-4695-94A7-8CCF64435358

P2860

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

http://www.wikidata.org/entity/Q37828337

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

@en

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

@nl

type

label

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

@en

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

@nl

prefLabel

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

@en

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

@nl

P1433

Q37828337-EE7BAC52-B183-498E-A33A-7367BDDF4B96

P1476

Q37828337-D9D49680-7E8E-49D6-8AE6-8207910D030B

P2093

Q37828337-31F0A82D-B7E2-45F1-B079-DD820BAE9B88

Q37828337-44E7C440-3B95-459C-B36F-044BCD70A090

Q37828337-E454030C-F532-4A33-9857-BE0306857E3B

Q37828337-ECB755DF-64F4-4B64-8842-80A1E31B0094

P2860

Q37828337-08F8651B-F446-4644-BC71-BF89F7FD116A

Q37828337-09056E07-7E21-4D1F-8BC9-06B004D62635

Q37828337-0ED8A9CE-C5A5-4761-AF7A-45595D05014D

Q37828337-17AE82EE-1EB9-4B2E-91BC-E26E84C98ABC

Q37828337-25574DE4-8C1E-4988-ADD5-CCB0A71AA2C4

Q37828337-267510AF-0AA7-4D88-9A90-4C4DE3064C12

Q37828337-284E7302-45DB-4C20-90B6-9B8212E9ED2A

Q37828337-2DFE9D67-2459-469F-8FD5-7E0B6D7211F0

Q37828337-343E7D34-B8BC-44C5-A536-CE5E7331BEFF

Q37828337-38DE452D-8C8A-4BF2-ACC0-DEC29A59ED53

P2888

Q37828337-028F44A7-9D24-4E67-87B4-861023DE757B

P304

Q37828337-905B7603-EF75-48E5-B526-FE0772E0D0FB

P31

Q37828337-6E95F8F0-3E1B-4652-8705-436B3ACD018F

P356

Q37828337-F39FB24C-2EEA-4898-8BA0-2152A9CEE8D6

P433

Q37828337-D382B6BE-F73A-4488-8992-5D352668C309

P478

Q37828337-BBC74677-8F74-4E3E-8934-59F44ED1F593

P577

Q37828337-CDF0AA89-60E0-40AD-952E-B86E4DEE1412

P698

Q37828337-EA44DE4E-AE22-4FB2-B104-C319DCFA4F91

P921

Q37828337-298CA2C1-FF4E-4B59-978B-6028EA6BAE97

P356

P1433

Journal of Endocrinological Investigation

P1476

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

@en

P2093

A Leonardini

http://www.w3.org/2001/XMLSchema#string

A Natalicchio

http://www.w3.org/2001/XMLSchema#string

F Giorgino

http://www.w3.org/2001/XMLSchema#string

L Laviola

http://www.w3.org/2001/XMLSchema#string

P2860

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Incretin mimetics as a novel therapeutic option for hepatic steatosis

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

The Physiology of Glucagon-like Peptide 1

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

Effects of intensive glucose lowering in type 2 diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

P2888

P304

69-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/BF03346698

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21233599

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes